Vitamin D Levels in Liver Transplantation Recipients Prospective Observational Study
NCT ID: NCT03234218
Last Updated: 2018-05-23
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
68 participants
Study Classification
OBSERVATIONAL
Study Start Date
2016-09-30
Study Completion Date
2017-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Interest in vitamin D has seen an unprecedented revival sparked by the finding that vitamin D has pleiotropic effects with an intriguing link to the critically ill patients. The recent VITdAL-ICU RCT found a significant difference in mortality in patients with severe deficiency when high doses of vitamin D supplementation were administered.
Vitamin D deficiency is extremely common in patients with chronic liver disease and/or cirrhosis. It seems to be a marker of severity of the disease, but also a possible contributing factor in determining poor outcomes.
Design of the study: Observational prospective study. Primary variable end point: Vitamin D at baseline, and POD (post-operative day) 1, 3, 7, 28.
Secondary variable end points: ICU length of stay; SAPS 2 and SOFA score at POD 1, 7; Days of mechanical ventilation; Hospital length of stay; Mortality at POD 28; Diagnosed invasive infections; Graft rejection in the first 28 days; Bilirubin and INR at POD 7 and 28.
SAFETY. The patient will not undergo to additional procedure during the study and will be asked for consent to treatment of personal data.
SAMPLE SIZE. Because of the lack of knowledge in this specific cohort no formal sample was calculated beforehand. The sample size will be defined by one-year clinical activity: about 60 consecutive patients.
STATISTICAL ANALYSIS. All statistical analysis and results will be assessed and reported as exploratory analysis. In order to describe the trend over time of the vitamin D levels, descriptive statistics such as mean, median, interquartile range and standard deviation will be evaluated. In addition, 95% confidence intervals for mean and standard deviation will be reported. Comparisons between two temporal observations will be assessed with paired t-test. Any univariate association between factors or covariates, will be explored. Statistical analyses will be done with SAS 9.4,
Vitamin D deficiency is extremely common in patients with chronic liver disease and/or cirrhosis. It seems to be a marker of severity of the disease, but also a possible contributing factor in determining poor outcomes.
Design of the study: Observational prospective study. Primary variable end point: Vitamin D at baseline, and POD (post-operative day) 1, 3, 7, 28.
Secondary variable end points: ICU length of stay; SAPS 2 and SOFA score at POD 1, 7; Days of mechanical ventilation; Hospital length of stay; Mortality at POD 28; Diagnosed invasive infections; Graft rejection in the first 28 days; Bilirubin and INR at POD 7 and 28.
SAFETY. The patient will not undergo to additional procedure during the study and will be asked for consent to treatment of personal data.
SAMPLE SIZE. Because of the lack of knowledge in this specific cohort no formal sample was calculated beforehand. The sample size will be defined by one-year clinical activity: about 60 consecutive patients.
STATISTICAL ANALYSIS. All statistical analysis and results will be assessed and reported as exploratory analysis. In order to describe the trend over time of the vitamin D levels, descriptive statistics such as mean, median, interquartile range and standard deviation will be evaluated. In addition, 95% confidence intervals for mean and standard deviation will be reported. Comparisons between two temporal observations will be assessed with paired t-test. Any univariate association between factors or covariates, will be explored. Statistical analyses will be done with SAS 9.4,
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of 25-OH-vitamin D3 on the Liver Transplant Recipients
NCT04111146
Liver Transplant Disorder
COMPLETED
Prevalence of Deficiency of Vitamin D in Critically Ill Patients
NCT03639584
Vitamin D Deficiency
Critical Illness
COMPLETED
Effect of Preoperative Vitamin D Supplementation in Liver Transplant Recipients With Vitamin D Deficiency on Post Transplant Outcomes
NCT06736093
Post Liver Transplant Infection
RECRUITING
NA
The Effect of Vitamin D Repletion in Patients With Hepatocellular Carcinoma on the Orthotopic Liver Transplant List
NCT01575717
Vitamin D Deficiency
Hepatocellular Carcinoma
UNKNOWN
NA
Vitamin D Supplementation in Cirrhotic Patients
NCT02009748
Cirrhosis
Vitamin D Deficiency
COMPLETED
PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
BACKGROUND Interest in vitamin D has seen an unprecedented revival sparked by the finding that vitamin D has pleiotropic effects. The nuclear vitamin D receptor (VDR) is widely present in different cell types and organs and regulates more than 200 genes.
The link between vitamin D and critical illness is new, but intriguing, because vitamin D deficiency
* has a very high prevalence in the ICU
* is strongly associated with excess morbidity and mortality
* is associated with increased susceptibility to sepsis thought its immunomodulating effects
* has a relation with acute kidney injury, acute respiratory failure, duration of mechanical ventilation and ARDS Critically ill patients are at high risk of mortality and standard care uses little or no vitamin D.
It may well be the case that vitamin D deficiency is indeed an "invisible accomplice to morbidity and mortality," as proposed by Paul Lee.
VITAMIN D IN PATIENTS WITH CHRONIC LIVER DISEASE AND/OR CIRRHOSIS Vitamin D deficiency is extremely common in patients with chronic liver disease and/or cirrhosis. It seems to be a marker of severity of the disease, but also a possible contributing factor in determining poor outcomes.
Mechanisms Low synthesis. Severe liver disease decreases vitamin D hydroxylation and albumin and DBP production. But lack of liver function is just one piece of the puzzle. Possible concomitant causes may include inadequate sun exposure, insufficient food intake, steroids, jaundice-related deterioration of vitamin synthesis on the skin, and decreased vitamin D absorption caused by intestinal edema secondary to portal hypertension or cholestasis-induced bile salt disruption.
Signaling disruption. Vitamin D plays a role in reducing risk of chronic diseases. This most likely results from local production of 1a25(OH)2D, with its autocrine and paracrine actions in cellular proliferation and differentiation. These effects may also be relevant in liver diseases.
Pro-inflammatory signals in monocytes and macrophages may regulate the local metabolism of vitamin D, and the local production of α25(OH)2D. Almost 90% of tissue macrophages are in the liver, suggesting that local production of vitamin D in liver inflammation is impaired.
Innate immunity. Vitamin D increases secretion of antibacterial proteins such as cathelicidin and beta-defensin, promotes chemotaxis and macrophage phagocytosis, and regulate the expression of several TLRs.
Adaptive immunity. Vitamin D seems to control excessive immune response by decreasing the expression of class II HLA complex, and by modulating T cells, inducing differentiation and expansion of regulatory T cells, which secrete IL-10 and TGF-β. This could explain an association between vitamin D deficiency and autoimmune liver damage. Moreover in vitro and in vivo studies of mouse models with liver fibrosis reported an anti-fibrotic effect for vitamin D.
Hepatitis C. Data have shown that vitamin D supplementation during interferon and ribavirin increased the level of sustained viral response. Furthermore, vitamin D seems to indirectly inhibit HCV replication in human hepatocytes by stimulating IFB beta production.
NAFLD. Non-alcoholic fatty liver disease is a clinical entity ranging from steatosis to non-alcoholic steatohepatitis and cirrhosis. Vitamin D deficiency has a possible role in it.
The impact of liver transplantation on vitamin D status: lack of knowledge Individual outcome after liver transplantation varies widely due to multi-factorial variables. Vitamin D has not been extensively evaluated in patients undergoing liver transplantation. In one cohort of patients, vitamin D deficiency was associated with acute cellular rejection. It is still unclear how it acts in the more critical days after transplantation, and what predictive role it may play.
The relevant role of calcium metabolism and vitamin D after solid organ transplantation has been highlighted by several meta-analyses in recent years, suggesting a possible impact on prognosis.
To stress the relevance of the topic even in such a complex surgical procedure, low vitamin D is associated with a worse outcome after various types of surgery.
Myriad considerations suggest its evaluation in liver transplantation recipients:
* Vitamin D deficiency is a global health problem.
* Patients affected with liver disease have much lower levels of vitamin D
* Causes of low levels of vitamin D may be low production, low sun exposure, reduced mobility, and other factors reducing the availability of vitamin D in the system.
* Vitamin D has pleiotropic effects, and seems to act mainly on the immunomodulating system. Infection is the main threat in the first 6 months after transplantation.
* The number of patients receiving marginal donor organs is increasing. In many of them the recovery of liver function proceeds slowly.
* Some liver recipients become severely ill during the ICU stay. In these patients there is a suspicion of severe vitamin D insufficiency.
* Incidence of acute kidney injury is very high in complicated liver transplantation.
* The VITdAL-ICU RCT found a reduced mortality in severe deficiency after high doses of vitamin D.
* Vitamin D may reveal itself as a marker of improving metabolic function, acting as a prognostic marker that may even contribute to outcome, and is easily modifiable.
Aims of the study Principal
\- Describe the level and the trend of vitamin D levels in liver transplantation recipients during the first 28 days after transplantation.
Secondary
* Explore the association between vitamin D level post-transplant and critical conditions (ICU stay, severity score, infections, mortality).
* Explore the association between vitamin D level post-transplant and pre-transplant conditions (vitamin D level and severity of liver disease).
* Explore the association between pre-transplant vitamin D level and outcome (mortality at 28 days).
* Explore the association between the quality of graft (marginal vs. standard) on post-transplant vitamin D level.
* Explore the association between vitamin D level and graft function.
* Explore the association between post-transplant vitamin D level and long term patient and graft outcomes.
Primary variable end point:
Vitamin D level measured at baseline, and POD (post-operative day) 1, 3, 7, 28. Secondary variable end points ICU length of stay SAPS 2 and SOFA score at POD 1, 7 Days of mechanical ventilation Hospital length of stay Mortality at POD 28 Diagnosed invasive infections Graft rejection in the first 28 days Bilirubin and INR at POD 7 and 28
Data collection and timing of the observations:
Vitamin D level and metabolism:
* Vitamin D at time of listing (wait list for liver transplantation); at time of hospital admission for liver transplantation; POD 1, 3, 7, 28
* Albumin POD 1, 3, 7, 28
* Parathormone (PTH) at time of hospital admission for transplantation, and on 1, 7, 28 SAFETY. Vitamin D levels will be measured in blood samples drawn during standard clinical practice. Clinical activity will follow well established protocols for liver transplants at our institute. Given the observational nature of the study, insurance for possible patient damage is waived.
The patient will be asked for consent to treatment of personal data. The person responsible for this privacy consent will be the principal investigator.
STATISTICAL ANALYSIS. Because this is an exploratory study, all statistical analysis and results will be assessed and reported as exploratory analysis. In order to describe the trend over time of the vitamin D levels in patients undergoing liver transplantation, descriptive statistics such as mean, median, interquartile range and standard deviation will be evaluated. In addition, 95% confidence intervals for mean and standard deviation will be reported. Comparisons between two temporal observations will be assessed with paired t-test.
In addition, mixed model repeated measures (MMRM) will be applied in order to assess the vitamin D trend level over PODs 1-7-28.
In order to assess the secondary aims, the same methods given above will be applied. In particular, for the secondary aim, for the association between quality of graft (marginal vs. standard) on post-transplant vitamin D level, a logistic analysis for repeated measures will be applied.
Any univariate association between factors or covariates, described in the data collection section, will be explored. In addition, multiple MMRM analyses will applied in order to explore association between vitamin D level and the most relevant variables.
All statistical analyses will be done with SAS 9.4, all results will be considered exploratory for statistical testing, and p-values will be reported as "nominally statistically significant." ANALYTICAL METHODS. Vitamin D will be measured with the Bio-Rad 25-OH Vitamin D3/D2 HPLC assay (High Performance Liquid Chromatography). Parathormone will be measured with a chemiluminescence technique using the IMMULITE® 2000 Intact PTH.
ANTICIPATED BENEFITS AND IMPACT OF FINDINGS. Vitamin D deficiency is a global health problem. This study would be an actual description of vitamin D status in a cohort of recipients of liver transplantation, indicating a possible group of patients in which routine measurement of serum vitamin D may be mandatory.
A high prevalence of severe deficiency may suggest starting later high dosage supplementation if new evidence confirms its positive effect in critically ill patients.
The link between vitamin D and critical illness is new, but intriguing, because vitamin D deficiency
* has a very high prevalence in the ICU
* is strongly associated with excess morbidity and mortality
* is associated with increased susceptibility to sepsis thought its immunomodulating effects
* has a relation with acute kidney injury, acute respiratory failure, duration of mechanical ventilation and ARDS Critically ill patients are at high risk of mortality and standard care uses little or no vitamin D.
It may well be the case that vitamin D deficiency is indeed an "invisible accomplice to morbidity and mortality," as proposed by Paul Lee.
VITAMIN D IN PATIENTS WITH CHRONIC LIVER DISEASE AND/OR CIRRHOSIS Vitamin D deficiency is extremely common in patients with chronic liver disease and/or cirrhosis. It seems to be a marker of severity of the disease, but also a possible contributing factor in determining poor outcomes.
Mechanisms Low synthesis. Severe liver disease decreases vitamin D hydroxylation and albumin and DBP production. But lack of liver function is just one piece of the puzzle. Possible concomitant causes may include inadequate sun exposure, insufficient food intake, steroids, jaundice-related deterioration of vitamin synthesis on the skin, and decreased vitamin D absorption caused by intestinal edema secondary to portal hypertension or cholestasis-induced bile salt disruption.
Signaling disruption. Vitamin D plays a role in reducing risk of chronic diseases. This most likely results from local production of 1a25(OH)2D, with its autocrine and paracrine actions in cellular proliferation and differentiation. These effects may also be relevant in liver diseases.
Pro-inflammatory signals in monocytes and macrophages may regulate the local metabolism of vitamin D, and the local production of α25(OH)2D. Almost 90% of tissue macrophages are in the liver, suggesting that local production of vitamin D in liver inflammation is impaired.
Innate immunity. Vitamin D increases secretion of antibacterial proteins such as cathelicidin and beta-defensin, promotes chemotaxis and macrophage phagocytosis, and regulate the expression of several TLRs.
Adaptive immunity. Vitamin D seems to control excessive immune response by decreasing the expression of class II HLA complex, and by modulating T cells, inducing differentiation and expansion of regulatory T cells, which secrete IL-10 and TGF-β. This could explain an association between vitamin D deficiency and autoimmune liver damage. Moreover in vitro and in vivo studies of mouse models with liver fibrosis reported an anti-fibrotic effect for vitamin D.
Hepatitis C. Data have shown that vitamin D supplementation during interferon and ribavirin increased the level of sustained viral response. Furthermore, vitamin D seems to indirectly inhibit HCV replication in human hepatocytes by stimulating IFB beta production.
NAFLD. Non-alcoholic fatty liver disease is a clinical entity ranging from steatosis to non-alcoholic steatohepatitis and cirrhosis. Vitamin D deficiency has a possible role in it.
The impact of liver transplantation on vitamin D status: lack of knowledge Individual outcome after liver transplantation varies widely due to multi-factorial variables. Vitamin D has not been extensively evaluated in patients undergoing liver transplantation. In one cohort of patients, vitamin D deficiency was associated with acute cellular rejection. It is still unclear how it acts in the more critical days after transplantation, and what predictive role it may play.
The relevant role of calcium metabolism and vitamin D after solid organ transplantation has been highlighted by several meta-analyses in recent years, suggesting a possible impact on prognosis.
To stress the relevance of the topic even in such a complex surgical procedure, low vitamin D is associated with a worse outcome after various types of surgery.
Myriad considerations suggest its evaluation in liver transplantation recipients:
* Vitamin D deficiency is a global health problem.
* Patients affected with liver disease have much lower levels of vitamin D
* Causes of low levels of vitamin D may be low production, low sun exposure, reduced mobility, and other factors reducing the availability of vitamin D in the system.
* Vitamin D has pleiotropic effects, and seems to act mainly on the immunomodulating system. Infection is the main threat in the first 6 months after transplantation.
* The number of patients receiving marginal donor organs is increasing. In many of them the recovery of liver function proceeds slowly.
* Some liver recipients become severely ill during the ICU stay. In these patients there is a suspicion of severe vitamin D insufficiency.
* Incidence of acute kidney injury is very high in complicated liver transplantation.
* The VITdAL-ICU RCT found a reduced mortality in severe deficiency after high doses of vitamin D.
* Vitamin D may reveal itself as a marker of improving metabolic function, acting as a prognostic marker that may even contribute to outcome, and is easily modifiable.
Aims of the study Principal
\- Describe the level and the trend of vitamin D levels in liver transplantation recipients during the first 28 days after transplantation.
Secondary
* Explore the association between vitamin D level post-transplant and critical conditions (ICU stay, severity score, infections, mortality).
* Explore the association between vitamin D level post-transplant and pre-transplant conditions (vitamin D level and severity of liver disease).
* Explore the association between pre-transplant vitamin D level and outcome (mortality at 28 days).
* Explore the association between the quality of graft (marginal vs. standard) on post-transplant vitamin D level.
* Explore the association between vitamin D level and graft function.
* Explore the association between post-transplant vitamin D level and long term patient and graft outcomes.
Primary variable end point:
Vitamin D level measured at baseline, and POD (post-operative day) 1, 3, 7, 28. Secondary variable end points ICU length of stay SAPS 2 and SOFA score at POD 1, 7 Days of mechanical ventilation Hospital length of stay Mortality at POD 28 Diagnosed invasive infections Graft rejection in the first 28 days Bilirubin and INR at POD 7 and 28
Data collection and timing of the observations:
Vitamin D level and metabolism:
* Vitamin D at time of listing (wait list for liver transplantation); at time of hospital admission for liver transplantation; POD 1, 3, 7, 28
* Albumin POD 1, 3, 7, 28
* Parathormone (PTH) at time of hospital admission for transplantation, and on 1, 7, 28 SAFETY. Vitamin D levels will be measured in blood samples drawn during standard clinical practice. Clinical activity will follow well established protocols for liver transplants at our institute. Given the observational nature of the study, insurance for possible patient damage is waived.
The patient will be asked for consent to treatment of personal data. The person responsible for this privacy consent will be the principal investigator.
STATISTICAL ANALYSIS. Because this is an exploratory study, all statistical analysis and results will be assessed and reported as exploratory analysis. In order to describe the trend over time of the vitamin D levels in patients undergoing liver transplantation, descriptive statistics such as mean, median, interquartile range and standard deviation will be evaluated. In addition, 95% confidence intervals for mean and standard deviation will be reported. Comparisons between two temporal observations will be assessed with paired t-test.
In addition, mixed model repeated measures (MMRM) will be applied in order to assess the vitamin D trend level over PODs 1-7-28.
In order to assess the secondary aims, the same methods given above will be applied. In particular, for the secondary aim, for the association between quality of graft (marginal vs. standard) on post-transplant vitamin D level, a logistic analysis for repeated measures will be applied.
Any univariate association between factors or covariates, described in the data collection section, will be explored. In addition, multiple MMRM analyses will applied in order to explore association between vitamin D level and the most relevant variables.
All statistical analyses will be done with SAS 9.4, all results will be considered exploratory for statistical testing, and p-values will be reported as "nominally statistically significant." ANALYTICAL METHODS. Vitamin D will be measured with the Bio-Rad 25-OH Vitamin D3/D2 HPLC assay (High Performance Liquid Chromatography). Parathormone will be measured with a chemiluminescence technique using the IMMULITE® 2000 Intact PTH.
ANTICIPATED BENEFITS AND IMPACT OF FINDINGS. Vitamin D deficiency is a global health problem. This study would be an actual description of vitamin D status in a cohort of recipients of liver transplantation, indicating a possible group of patients in which routine measurement of serum vitamin D may be mandatory.
A high prevalence of severe deficiency may suggest starting later high dosage supplementation if new evidence confirms its positive effect in critically ill patients.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Liver Transplant Disorder
Vitamin D Deficiency
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* All recipients of liver transplantation at Ismett, aged 18 or more
Exclusion Criteria
* Lack of informed consent for the treatment of personal data. otherwise all the patients will be included if the accept to sign the informed consent
Minimum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Gennaro Martucci, MD
Role: PRINCIPAL_INVESTIGATOR
The Mediterranean Institute for Transplantation and Advanced Specialized Therapies
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ismett
Palermo, , Italy
Site Status
Countries
Review the countries where the study has at least one active or historical site.
Italy
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRRB/12/16
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Prediction Model of Vitamin D Deficiency
NCT05376774
COMPLETED
Serum Vitamin D Levels in Critically Ill Patients Undergoing Regional Citrate Anticoagulation CRRT
NCT02414386
COMPLETED
Vitamin D to Improve Outcomes by Leveraging Early Treatment
NCT03096314
COMPLETED
PHASE3
VITdAL@ICU - Correction of Vitamin D Deficiency in Critically Ill Patients
NCT01130181
COMPLETED
PHASE3
VITamine D Supplementation in RenAL Transplant Recipients - VITALE
NCT01431430
COMPLETED
PHASE4
Validation of Prediction Model of Vitamin D Deficiency
NCT05094388
RECRUITING
The VITDALIZE Study: Effect of High-dose Vitamin D3 on 28-day Mortality in Adult Critically Ill Patients
NCT03188796
RECRUITING
PHASE3
Relationship Between Serum Vitamin D and Outcomes of Liver Transplantation in Cirrhotic Patients Undergoing Liver Transplantation and Effects of Vitamin D Supplementation in Post-transplant Period
NCT05568836
UNKNOWN
PHASE1/PHASE2
Vitamin D3 Substitution in Vitamin D Deficient Kidney Transplant Recipients
NCT00752401
UNKNOWN
PHASE3
Vitamin D Replacement in Nonalcoholic Fatty Liver Disease
NCT03084328
COMPLETED
Preventive and Reversional Effect of Vitamin D on Parenteral Nutrition Associated Liver Disease
NCT02452177
UNKNOWN
NA
Vitamin D and Outcome in Cardiac Surgery
NCT02192528
COMPLETED
Optimizing Vitamin D Nutrition in Healthy Adults
NCT00327847
COMPLETED
NA
Vitamin A Liver Reserves and Serum Markers of Vitamin A in US Adults at Time of Death
NCT03305042
COMPLETED
Effects of Enteral Supplement Vitamin D Incritically Ill Patients
NCT04292873
COMPLETED
NA
Association of Low Vitamin D Levels With Mortality in Patients With Reduced Left Ventricular Function Referred to Cardiac Surgery
NCT00741546
UNKNOWN
Vitamin D Insufficiency inVestigation Among hospitaLizeD Inpatients
NCT05214040
NOT_YET_RECRUITING
Vitamin D and Mortality: an Individual Participant Data Meta-analysis of Standardized 25-hydroxyvitamin D
NCT02438488
COMPLETED
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
NCT01956864
WITHDRAWN
PHASE1
Replenishing and Maintaining Vitamin D Status in Older Adults in Residential Care Facilities in NI
NCT04395638
SUSPENDED
NA
VitamIN D Treating patIents With Chronic heArT failurE
NCT01619891
COMPLETED
PHASE2
A Single Wintertime Dose of Vitamin D3 to Prevent Winter Decline in Vitamin D Status in Healthy Adults
NCT01924910
COMPLETED
PHASE4
Vitamin D Status and Supplementation in Athletes
NCT02008201
COMPLETED
PHASE3
Vitamin D Improves Depression in Liver Patients
NCT02359266
COMPLETED
NA
Vitamin D Level and Risk of Infections in Cirrhotic Patients
NCT03391245
UNKNOWN